In 4Q07, Atripla’s US Rx share in the first line rose to 55% (from 53% in the pie chart in #msg-25102913), while GILD’s overall share of US Rx’s in the first line remained close to 80%.
In the overall US market (first line plus later lines), Atripla’s Rx share is now 25% and GILD's overall share of RX's is 65%.
Source: Today’s GILD CC
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”